IMC Chicago
VKTX icon

IMC Chicago’s Viking Therapeutics VKTX Stock Holding History

IMC Chicago’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.71M Sell
298,500
-27,600
-8% -$887K ﹤0.01% 1290
2025
Q4 		$11.5M Sell
326,100
-21,900
-6% -$776K ﹤0.01% 1126
2025
Q3 		$9.15M Buy
348,000
+241,000
+225% +$7.19M ﹤0.01% 1194
2025
Q2 		$2.84M Buy
+107,000
New +$2.82M ﹤0.01% 1765

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

IMC Chicago's VKTX Position: Q1 2026 in Review

IMC Chicago increased its Viking Therapeutics (VKTX) stake by 79% in Q1 2026, buying an estimated $447K and bringing the position to 31,426 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3256.

IMC Chicago first reported a position in VKTX in Q2 2025 and has held it in 4 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • IMC Chicago held 31,426 shares of Viking Therapeutics worth $1.02M as of Q1 2026.
  • IMC Chicago bought 13,913 Viking Therapeutics shares in Q1 2026, an estimated $447K.
  • Viking Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #3256 holding.
  • IMC Chicago first reported a position in Viking Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.